Compare ProShares Ultra QQQ ETF (QLD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ProShares Ultra QQQ ETF trades at $89.3, while State Street SPDR S&P Biotech ETF trades at $159.61. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| QLD | XBI | |
|---|---|---|
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $100.53 | $169.55 |
52-Week Low | $57.16 | $93.43 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD trades at $90.53, down 0.17% on the day. The technical outlook is bullish, with moving averages signaling strength and support at $90. Recent news highlights institutional buying, with 180 Wealth Advisors increasing its stake by 29.4% in Q2 2026. The ETF has delivered over 10,000% total return since inception, demonstrating long-term compounding power.
Outlook remains positive for investors seeking leveraged Nasdaq-100 exposure, but risks include daily rebalancing decay and market volatility. The ETF suits tactical allocations given its bullish technicals and institutional interest, though it requires active risk management due to its leveraged structure.
XBI (SPDR S&P Biotech ETF) trades at $161.97, down 1.12% on the day, with a bearish technical signal overall despite bullish moving averages. The ETF holds over 150 biotech companies, benefiting from strong M&A activity and positive clinical catalysts, though key financial ratios are not applicable for the fund structure. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic given sector tailwinds, but high volatility and concentration in small-cap biotech pose risks. The single analyst covering the ETF maintains a Hold rating, reflecting a neutral stance amid the sector's rally and inherent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
